放、化疗联合免疫治疗晚期肿瘤的临床研究与护理

目的 观察晚期肿瘤患者进行放化疗联合免疫治疗对PS评分和临床表现的影响。方法 共80例晚期肿瘤患者,其中40例在放化疗的同时输入共刺激的正常人外周血淋巴细胞(PBLs)进行免疫治疗,每周2次,8次为一疗程。另40例为对照组,仅接受放、化疗。观察两组患者的PS评分及临床表现,进行对照研究。结果 放、化疗联合免疫治疗组治疗前后比较PS评分下降显著,P<0.001,临床表现改善明显。对照组治疗前后比较PS评分有下降,但差异无显著性,P>0.05,临床表现有改善,但不明显。比较治疗后两组临床表现各项指标,疼痛P<0.05,其余均为P<0.01,亦差异具有显著性。结论 免疫治疗与放化疗联合治疗,有利于减轻放化疗的副作用,提高疗效,改善生活质量。

Clinical Study and Nursing of Late Carcinoma Treating with Radiotherapy and Chemicotherapy Plus Immu-notherapy

Objective To observe the influence factor on PS score and clinical manifestation. Methods 80 cases of late carcinoma patients were drvided into the treatment group (40 Cases) and the control group (40 Cases). Patients in the treatment group receive radiotherapy and Chemicotherapy. Meanwhile all patients receive immunotherapy PBLs two times a week, eight times is a course of treatment. Patients in the control group only were given radiotherapy and chemicotherapy. Then the PSS scores and clinical manifestations of two groups were compared. Results Radiotherapy and chemicotherapy Plus immunotherapy can decrease PS scores, P <0. 001, also improve the clinical manifestation. In the control group, Ps scores decreased after treatment, but there were no significant differences, P> 0. 05, the clinical manifestations improved little. Compared the indexes of clinical manifestations of two groups, there were significant differences P <0. 05 or P <0. 01. Conclusions Radiotherapy and Chemicotherapy plus immunotherapy can lighten the treatment side reaction, raise therapeutic effect and improve life quality.